Funding
Funding not disclosed
Founders
Product
Problem
Acute decompensated heart failure (ADHF) is a critical condition often accompanied by worsening renal function, leading to high mortality and frequent hospital readmissions. Existing treatments for ADHF and associated cardio-renal syndrome are frequently ineffective, necessitating novel therapeutic approaches.
Solution
QHeart Medical is developing the Transcatheter Aortic Recoil Repair (TARR) implant, a pumpless, endovascular device designed to augment cardiac output and improve renal perfusion in patients with acute heart failure. The TARR device is delivered via femoral artery access and passively interacts with the heart's natural pumping cycle, dampening pressure during systole and recoiling during diastole. This mechanism aims to enhance stroke volume and blood flow to vital organs, offering a less invasive and potentially more effective treatment option compared to existing mechanical circulatory support systems. The technology is intended for both acute in-hospital treatment and potential longer-term management of heart failure patients.
Target Audience
The primary target audience includes cardiologists, interventional cardiologists, and hospital systems treating patients with acute decompensated heart failure, particularly those experiencing worsening renal function.
Features
- Transcatheter implant delivered via femoral artery access for minimally invasive deployment.
- Pumpless, self-powered design that leverages the heart's natural mechanics for therapy.
- Passive dampening and recoil action to improve cardiac output and stroke volume.
- Enhanced blood flow to kidneys, addressing cardio-renal syndrome and worsening renal function.
- Designed for acute in-hospital treatment (up to 7 days) and potential longer-term application.
- Wireless monitoring capabilities for in-hospital patient mobility.
- Blood-friendly design intended to minimize hemolysis and acute kidney injury.